From Scientific Affairs, American Red Cross, Gaithersburg, MD (E.D.M., C.S.W., L.T., R.L.T., R.Y.D., S.L.S.); and the Research Division, Imugen, Norwood, MA (V.P.B., M.-E.H., K.E.W.).
N Engl J Med. 2016 Dec 8;375(23):2236-2245. doi: 10.1056/NEJMoa1600897.
Babesia microti, a tickborne intraerythrocytic parasite that can be transmitted by means of blood transfusion, is responsible for the majority of cases of transfusion-transmitted babesiosis in the United States. However, no licensed test exists for screening for B. microti in donated blood. We assessed data from a large-scale, investigational product-release screening and donor follow-up program.
From June 2012 through September 2014, we performed arrayed fluorescence immunoassays (AFIAs) for B. microti antibodies and real-time polymerase-chain-reaction (PCR) assays for B. microti DNA on blood-donation samples obtained in Connecticut, Massachusetts, Minnesota, and Wisconsin. We determined parasite loads with the use of quantitative PCR testing and assessed infectivity by means of the inoculation of hamsters and the subsequent examination for parasitemia. Donors with test-reactive samples were followed. Using data on cases of transfusion-transmitted babesiosis, we compared the proportions of screened versus unscreened donations that were infectious.
Of 89,153 blood-donation samples tested, 335 (0.38%) were confirmed to be positive, of which 67 (20%) were PCR-positive; 9 samples were antibody-negative (i.e., 1 antibody-negative sample per 9906 screened samples), representing 13% of all PCR-positive samples. PCR-positive samples were identified all through the year; antibody-negative infections occurred from June through September. Approximately one third of the red-cell samples from PCR-positive or high-titer AFIA-positive donations infected hamsters. Follow-up showed DNA clearance in 86% of the donors but antibody seroreversion in 8% after 1 year. In Connecticut and Massachusetts, no reported cases of transfusion-transmitted babesiosis were associated with screened donations (i.e., 0 cases per 75,331 screened donations), as compared with 14 cases per 253,031 unscreened donations (i.e., 1 case per 18,074 unscreened donations) (odds ratio, 8.6; 95% confidence interval, 0.51 to 144; P=0.05). Overall, 29 cases of transfusion-transmitted babesiosis were linked to blood from infected donors, including blood obtained from 10 donors whose samples tested positive on the PCR assay 2 to 7 months after the implicated donation.
Blood-donation screening for antibodies to and DNA from B. microti was associated with a decrease in the risk of transfusion-transmitted babesiosis. (Funded by the American Red Cross and Imugen; ClinicalTrials.gov number, NCT01528449 .).
巴贝西虫是一种通过输血传播的血内寄生性寄生虫,是美国大多数输血传播巴贝西虫病病例的罪魁祸首。然而,目前尚无用于筛查献血中巴贝西虫的许可检测。我们评估了一项大规模、研究性产品放行筛查和供者随访计划的数据。
从 2012 年 6 月至 2014 年 9 月,我们对在康涅狄格州、马萨诸塞州、明尼苏达州和威斯康星州采集的献血样本进行了巴贝西虫抗体的阵列荧光免疫分析(AIFA)和巴贝西虫 DNA 的实时聚合酶链反应(PCR)检测。我们使用定量 PCR 检测来确定寄生虫载量,并通过接种仓鼠和随后检查是否有寄生虫血症来评估感染性。对检测呈阳性的供者进行了随访。我们利用输血传播巴贝西虫病的病例数据,比较了筛查与未筛查献血的感染比例。
在 89153 份血液检测样本中,有 335 份(0.38%)经确认呈阳性,其中 67 份(20%)为 PCR 阳性;9 份为抗体阴性(即每 9906 份筛查样本中就有 1 份抗体阴性样本),占所有 PCR 阳性样本的 13%。PCR 阳性样本全年均有检出;抗体阴性感染发生在 6 月至 9 月。大约三分之一来自 PCR 阳性或高滴度 AIFA 阳性的红细胞样本的捐赠者感染了仓鼠。随访显示,86%的供者清除了 DNA,但 8%的供者在 1 年后出现抗体血清学转换。在康涅狄格州和马萨诸塞州,与未筛查献血(即每 75331 份筛查献血中有 0 例)相比,未筛查献血中没有报告与筛查献血相关的输血传播巴贝西虫病病例(即每 253031 份未筛查献血中有 14 例)(比值比,8.6;95%置信区间,0.51 至 144;P=0.05)。总的来说,有 29 例输血传播巴贝西虫病与受感染者的血液有关,包括 10 名供者的血液,这些供者的样本在受感染供者的血液采集后 2 至 7 个月时通过 PCR 检测呈阳性。
对巴贝西虫抗体和 DNA 的血液筛查与输血传播巴贝西虫病的风险降低有关。(由美国红十字会和 Imugen 资助;临床试验.gov 编号,NCT01528449)。